Tardive dyskinesia and essential fatty acids

Area of Science:

• Neuroscience
• Pharmacology
• Nutritional Science

Background:

• Tardive dyskinesia (TD) is a neurological movement disorder associated with anti-dopaminergic medications.
• Its pathophysiology involves complex mechanisms including dopaminergic supersensitivity and neurotransmitter imbalances.
• Essential fatty acids (EFAs) are crucial for neuronal membrane function and integrity.

Purpose of the Study:

• To explore the role of essential fatty acids (EFAs) in the pathophysiology of tardive dyskinesia (TD).
• To review the potential of EFA supplementation as a therapeutic strategy for TD.
• To identify the need for further research into EFA and antioxidant interventions for TD.

Main Methods:

• Review of existing literature on TD pathophysiology and EFA metabolism.
• Analysis of studies investigating EFA levels in patients with TD.
• Examination of clinical trials and animal models testing EFA, antioxidant, and melatonin supplementation for TD.

Main Results:

• Individuals with moderate to severe TD exhibit lower red blood cell (RBC) and plasma EFA levels.
• Preliminary studies suggest potential benefits of EFA (omega-3, omega-6, ethyl-EPA) and antioxidant (Vitamin E) supplementation in TD.
• Current evidence is limited by small sample sizes and short study durations.

Conclusions:

• Lower EFA levels may be implicated in the development or severity of TD.
• EFA supplementation shows promise but requires more rigorous investigation.
• Large, multi-center studies are essential to establish the efficacy and safety of EFAs and antioxidants for TD.